tenacissimoside A
| Name | Tenacissoside G | ||
| PubChem CID | 44561398 | ||
| Molecular Weight | 792.9g/mol | ||
| Synonyms |
tenacissimoside A |
||
| Formula | C₄₂H₆₄O₁₄ | ||
| SMILES | CC=C(C)C(=O)OC1C2C3(CCC(CC3CCC24C5(O4)CCC(C5(C1OC(=O)C)C)C(=O)C)OC6CC(C(C(O6)C)OC7C(C(C(C(O7)C)O)OC)O)OC)C | ||
| InChI | 1S/C42H64O14/c1-11-20(2)37(47)54-34-35-39(7)15-13-26(53-29-19-28(48-9)32(23(5)50-29)55-38-31(46)33(49-10)30(45)22(4)51-38)18-25(39)12-16-41(35)42(56-41)17-14-27(21(3)43)40(42,8)36(34)52-24(6)44/h11,22-23,25-36,38,45-46H,12-19H2,1-10H3/b20-11+/t22-,23-,25+,26+,27+,28-,29+,30-,31-,32-,33-,34+,35-,36-,38+,39+,40+,41+,42-/m1/s1 | ||
| InChIKey | OHDJGUWKOIBIKY-SGFNNURDSA-N | ||
| ChEMBL ID | CHEMBL464723 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | TongGuanTeng | ||
| Use Part | Stem, root or leaf | ||
| Flavor | Bitter | ||
| Meridian Tropism | Lung | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Gentianales
-->Family: Apocynaceae
-->Genus: Gongronemopsis
-->Species: Gongronemopsis tenacissima
|
||
| Pair Name | Tenacissoside G, Fluorouracil | |||
| Partner Name | Fluorouracil | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP8 | hsa841 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Expression | CCND1 | hsa595 | |
| Down-regulation | Expression | CDK2 | hsa1017 | |
| Down-regulation | Expression | CDK4 | hsa1019 | |
| Down-regulation | Expression | CDK6 | hsa1021 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Phosphorylation | TP53 | hsa7157 | |
| In Vitro Model | RKO | Colon carcinoma | Homo sapiens (Human) | CVCL_0504 |
| In Vivo Model | RKO cells at a density of 3×10⁶/ml were suspended in cold PBS, and a volume of 100 μl cell suspension was administrated subcutaneously in the right flank of each mouse. | |||
| Result | TG potentiated 5-FU's inhibitory activity to human colorectal cancer through arresting cell cycle progression and inducing p53-mediated apoptosis, which may present a novel strategy in CRC therapies and contribute to the optimizing clinical application of 5-FU. | |||
